Emergent BioSolutions (EBS) Accounts Payables (2010 - 2026)

Emergent BioSolutions' Accounts Payables history runs 17 years deep, the most recent figure standing at $39.5 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 32.01% year-over-year to $39.5 million; the TTM figure through Mar 2026 stood at $39.5 million (down 32.01% YoY), while the FY2025 annual figure was $55.6 million, down 8.7% from the prior year.
• Accounts Payables was $39.5 million for Q1 2026 at Emergent BioSolutions, down from $55.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $124.2 million in Q1 2023 to a low of $39.5 million in Q1 2026.
• Historically, Accounts Payables has averaged $87.6 million across 5 years, with a median of $100.2 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables increased 15.75% in 2023, then plunged 45.72% in 2024.
• A 5-year view of Accounts Payables shows it stood at $103.5 million in 2022, then rose by 8.41% to $112.2 million in 2023, then tumbled by 45.72% to $60.9 million in 2024, then slipped by 8.7% to $55.6 million in 2025, then fell by 28.96% to $39.5 million in 2026.
• The last three Accounts Payables figures came in at $39.5 million (Q1 2026), $55.6 million (Q4 2025), and $57.4 million (Q3 2025), per Business Quant data.